2010 NPT Review Conference

Armatec Global Appoints Former UN Ambassador Libran N. Cabactulan as Chair of the Advisory Board

Retrieved on: 
Thursday, May 25, 2023
Advisory board, United Nations, Multilateralism, Interview, Assembly, National Population Commission, Commission, Policy, Economy, United Nations Economic and Social Council, Broadband Commission for Sustainable Development, 2010 NPT Review Conference, United Nations Development Programme, NPT, Sustainable development, Conference, General assembly, Retail, Management

SYDNEY, May 24, 2023 /PRNewswire-PRWeb/ -- Armatec Global, an innovative provider of advanced technology solutions for the defence, critical infrastructure, and private and public sectors, is proud to announce the appointment of former United Nations Ambassador Libran N Cabactulan as the Chair of its Advisory Board. Ambassador Cabactulan brings a wealth of experience, global insights, and diplomatic expertise to Armatec Global, further strengthening the company's strategic vision and global presence.

Key Points: 
  • Ambassador Cabactulan brings a wealth of experience, global insights, and diplomatic expertise to Armatec Global, further strengthening the company's strategic vision and global presence.
  • Ambassador Cabactulan brings a wealth of experience, global insights, and diplomatic expertise to Armatec Global, further strengthening the company's strategic vision and global presence.
  • "As Chair of the Advisory Board, Ambassador Cabactulan will provide strategic counsel, guide policy engagement, and ensure that Armatec Global's activities align with international best practices and standards.
  • "I am excited to join Armatec Global and contribute my insights from years of diplomatic work," Ambassador Cabactulan said.

Buddhist Leader Calls on States to Commit to "No First Use" of Nuclear Weapons in Advance of NPT Meeting

Retrieved on: 
Wednesday, July 27, 2022
Education, United Kingdom, State, Tenth, 2010 NPT Review Conference, Nuclear weapon, Culture, SGI, Climate change, Risk, COVID-19, Soka Gakkai International, Conference, Ikeda, UN, Anglo-French Wars, Policy, Review, Headquarters of the United Nations, Lists of weapons, NPT, No, Weapon

Ikeda urges: "We must remember that it was never the purpose of the NPT to establish continuing nuclear threat and confrontation as the inevitable fate of humankind." He asks us to learn from the world's hibakusha -- the victims of the Hiroshima and Nagasaki bombings and the testing of nuclear weapons -- who insist that no one anywhere should suffer what they have endured.

Key Points: 
  • Today the risk that nuclear weapons will be used is at its highest level since the Cold War.
  • Ikeda urges: "We must remember that it was never the purpose of the NPT to establish continuing nuclear threat and confrontation as the inevitable fate of humankind."
  • On August 4, during the NPT Review Conference, the SGI will hold a side event promoting No First Use together with other like-minded organizations.
  • Every year since 1983, Ikeda has authored peace proposals offering concrete approaches to resolving the complex global issues facing humanity, centering on the need to abolish nuclear weapons.

Buddhist Leader Calls on States to Commit to "No First Use" of Nuclear Weapons in Advance of NPT Meeting

Retrieved on: 
Wednesday, July 27, 2022
Education, United Kingdom, State, Tenth, 2010 NPT Review Conference, Nuclear weapon, Culture, SGI, Climate change, Risk, COVID-19, Soka Gakkai International, Conference, Ikeda, UN, Anglo-French Wars, Policy, Review, Headquarters of the United Nations, Lists of weapons, NPT, No, Weapon

Ikeda urges: "We must remember that it was never the purpose of the NPT to establish continuing nuclear threat and confrontation as the inevitable fate of humankind." He asks us to learn from the world's hibakusha -- the victims of the Hiroshima and Nagasaki bombings and the testing of nuclear weapons -- who insist that no one anywhere should suffer what they have endured.

Key Points: 
  • Today the risk that nuclear weapons will be used is at its highest level since the Cold War.
  • Ikeda urges: "We must remember that it was never the purpose of the NPT to establish continuing nuclear threat and confrontation as the inevitable fate of humankind."
  • On August 4, during the NPT Review Conference, the SGI will hold a side event promoting No First Use together with other like-minded organizations.
  • Every year since 1983, Ikeda has authored peace proposals offering concrete approaches to resolving the complex global issues facing humanity, centering on the need to abolish nuclear weapons.

Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting

Retrieved on: 
Tuesday, March 8, 2022
NASDAQ, Safety, Time, AACR, Clinical trial, Annual report, Private Securities Litigation Reform Act, Research, U.S. Securities and Exchange Commission, 2010 NPT Review Conference, Failure, Cancer, PLANET, Titan, Form 10-K, MD, Antigen, Risk, GLOBE, Patient, Security (finance), American Association, ATLAS, COVID-19, Association, Interleukin, American Association for Cancer Research, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present clinical, preclinical, and manufacturing data at next month’s American Association for Cancer Research (AACR) Annual Meeting 2022 to be held from April 8-13 in New Orleans. The findings include late-breaking clinical data from the TiTAN™ clinical trial for the neoantigen-targeted peripheral T cell therapy product candidate GEN-011, results demonstrating successful production of GEN-011 using Genocea’s PLANET™ manufacturing process, and new preclinical data on Inhibigens™, antigens of suppressive immune responses uniquely identifiable by Genocea’s ATLAS™ platform.

Key Points: 
  • Of the patient samples entering PLANET, 100% have either successfully yielded a released drug product or are in process.
  • By taking a comprehensive approach to neoantigen identification, we are creating new and potentially more effective cell therapies for patients.
  • Details on poster presentations for the TiTAN clinical trial patient data, the PLANET manufacturing process and Inhibigens are shared below.
  • NPTs have minimal bystander, non-tumor-specific cells, and are devoid of Inhibigen-specific cells which may be detrimental to clinical response.